Achillion Pharma (ACHN), Gilead (GILD) Decline; Biotech Pressured
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Generic Sovaldi For Poor Countries is 'Nothing New', Says RBC (GILD)
September 5, 2014 11:17 AM EDTRBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $115. Analyst Michael J. Yee discussed today's weakness in the stock, linking it to reports of a cheaper version of Sovaldi offered in poor countries. In his view this is "nothing new."
"Based on our conversations with investors, we believe recent weakness this morning (stock was down as much as 8% intraday) was attributable to at least one media article and headline... More
